The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
03-Mar-16
$NA
Target:
Perseus Books LLC
Acquiror:
Ingram Content Group Inc.
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its client services business to Ingram Content Group Inc.
01-Mar-16
$NA
Target:
Perseus Books LLC
Acquiror:
Hachette Book Group, Inc.
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its publishing business to Hachette Book Group, Inc.
15-Dec-15
$4.3 billion
Target:
Heartland Payment Systems, Inc.
Acquiror:
Global Payments Inc.
Advised Heartland Payment Systems, Inc., one of the nation’s largest payment companies, on its sale to Global Payments Inc., a leading worldwide provider of payment technology services
29-Oct-15
$275 million
Target:
Aesynt, Inc.
Acquiror:
Omnicell, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
28-Sep-15
$NA
Target:
Alcoa Inc.
Advised Alcoa Inc. on its separation into two independent, publicly-traded companies
10-Sep-15
$NA
Target:
International Medical Group, Inc.
Acquiror:
ABRY Partners
Advised International Medical Group, Inc., a leader in the global insurance and assistance services market, on its sale to ABRY Partners
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
06-Jul-15
$910 million
Target:
Altegra Health, Inc.
Acquiror:
Emdeon Inc.
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
29-May-15
$4.1 billion
Target:
Telecity Group plc
Acquiror:
Equinix, Inc.
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
26-May-15
$2.2 billion
Target:
Nordstrom, Inc. (Credit Card Assets)
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets
09-Mar-15
$1.5 billion
Target:
RTI International Metals, Inc
Acquiror:
Alcoa Inc.
Advised Alcoa Inc. on the acquisition of RTI International Metals, Inc., a leading producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components, principally for the commercial aerospace and defense sectors
23-Feb-15
$NA
Target:
Softcard (JVL Ventures, LLC)
Acquiror:
Google Inc.
Advised Softcard, a joint venture of AT&T, Verizon and T-Mobile focused on mobile payments and commerce, on the sale of certain assets to Google
20-Feb-15
$800 million
Target:
GFI Group Inc.
Acquiror:
BGC Partners, Inc.
Advised the Special Committee of GFI Group Inc. on its sale to BGC Partners, Inc.
05-Feb-15
$10.5 billion
Target:
Wireline assets of Verizon Communications in California, Florida and Texas
Acquiror:
Frontier Communications
Advised the Board of Directors of Frontier in connection with its acquisition of wireline assets from Verizon in California, Florida and Texas
15-Dec-14
$NA
Target:
TITAL GmbH
Acquiror:
Alcoa Inc.
Advised Alcoa Inc. on the acquisition of TITAL GmbH, a privately-held German manufacturer of aluminum and titanium castings predominately for the aerospace and defense end markets
03-Sep-14
$300 million
Target:
Voya Financial, Inc.
Advised the Independent Committee of the Board of Directors of Voya Financial, Inc. in connection with Voya Financial, Inc.’s repurchase of 7.7mm shares (aggregate repurchase of $300mm) from ING Groep N.V.
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
05-Aug-14
$1.8 billion
Target:
Cars.com
Acquiror:
Gannett Co., Inc.
Advised Gannett Co., Inc. a media and marketing solutions company, on its acquisition of Cars.com (part of Classified Ventures, LLC), a provider of online auto advertising solutions and consumer content.
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
01-Aug-14
$NA
Target:
Global Trade Information Services, Inc.
Acquiror:
IHS Inc.
Advised Global Trade Information Services, the world’s leading supplier of international merchandise trade data, on the sale of the company to IHS.
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
26-Jun-14
$2.7 billion
Target:
Frank Russell Company
Acquiror:
London Stock Exchange Group plc
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
26-Jun-14
$2.9 billion
Target:
Firth Rixson Limited
Acquiror:
Alcoa Inc.
Advised Alcoa Inc. on the acquisition of Firth Rixson Limited, a leading provider of highly engineered rings, industrial forgings and specialized metal products primarily to the aerospace industry